Twist Bioscience Co. (NASDAQ:TWST) Receives $51.22 Consensus Target Price from Brokerages

Shares of Twist Bioscience Co. (NASDAQ:TWST) have been assigned an average recommendation of “Moderate Buy” from the nine analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $51.78.

A number of brokerages have commented on TWST. Scotiabank boosted their price objective on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday. Leerink Partners boosted their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. boosted their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Barclays cut their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, Robert W. Baird boosted their price target on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research note on Tuesday.

Twist Bioscience Price Performance

Shares of TWST opened at $41.89 on Tuesday. The stock’s 50-day moving average is $43.93 and its two-hundred day moving average is $46.15. The stock has a market cap of $2.49 billion, a PE ratio of -11.57 and a beta of 1.78. Twist Bioscience has a 12 month low of $23.07 and a 12 month high of $60.90.

Insider Activity at Twist Bioscience

In other news, insider Dennis Cho sold 659 shares of the company’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $27,388.04. Following the completion of the transaction, the insider now directly owns 94,481 shares of the company’s stock, valued at approximately $3,926,630.36. This represents a 0.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Robert F. Werner sold 1,448 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $64,580.80. Following the transaction, the chief accounting officer now directly owns 45,620 shares of the company’s stock, valued at $2,034,652. This trade represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,118 shares of company stock valued at $4,391,151 over the last three months. 3.92% of the stock is owned by insiders.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors have recently made changes to their positions in TWST. State Street Corp grew its holdings in Twist Bioscience by 19.9% in the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after buying an additional 526,028 shares in the last quarter. Geode Capital Management LLC grew its holdings in Twist Bioscience by 1.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock worth $61,807,000 after buying an additional 26,145 shares in the last quarter. Thrivent Financial for Lutherans acquired a new stake in Twist Bioscience in the third quarter worth approximately $43,992,000. Wellington Management Group LLP lifted its position in Twist Bioscience by 188.5% in the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after purchasing an additional 521,272 shares during the period. Finally, Fred Alger Management LLC lifted its position in Twist Bioscience by 17.1% in the third quarter. Fred Alger Management LLC now owns 767,149 shares of the company’s stock worth $34,660,000 after purchasing an additional 112,272 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.